Gracell Bio (GRCL) Stock Forecast, Price Target & Predictions
GRCL Stock Forecast
Gracell Bio stock forecast is as follows: an average price target of $6.00 (represents a -41.46% downside from GRCL’s last price of $10.25) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
GRCL Price Target
GRCL Analyst Ratings
Buy
Gracell Bio Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 08, 2022 | - | H.C. Wainwright | $6.00 | $2.63 | 128.14% | -41.46% |
10
Gracell Bio Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $10.25 | $10.25 | $10.25 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 22, 2022 | Citigroup | - | Negative | Initialise |
Jun 01, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Apr 04, 2022 | BTIG | - | Buy | Initialise |
10
Gracell Bio Financial Forecast
Gracell Bio Revenue Forecast
Quarter
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $366.00K |
Avg Forecast | - | - | - | - | - | - | $125.00K | $366.00K | $366.00K |
High Forecast | - | - | - | - | - | - | $88.83K | $260.09K | $439.20K |
Low Forecast | - | - | - | - | - | - | $146.28K | $428.30K | $292.80K |
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
Surprise % | - | - | - | - | - | - | - | - | 1.00% |
Forecast
Gracell Bio EBITDA Forecast
Quarter
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
EBITDA | - | - | - | - | - | - | $-151.34M | $-127.26M | $-128.20M |
Avg Forecast | - | - | - | - | - | - | $75.00K | $219.60K | $-128.20M |
High Forecast | - | - | - | - | - | - | $53.30K | $156.06K | $-102.56M |
Low Forecast | - | - | - | - | - | - | $87.77K | $256.98K | $-153.84M |
Surprise % | - | - | - | - | - | - | -2017.83% | -579.50% | 1.00% |
Forecast
Gracell Bio Net Income Forecast
Quarter
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
Net Income | - | - | - | - | - | - | $-151.73M | $-116.26M | $-129.28M |
Avg Forecast | $105.23M | $91.66M | $107.62M | $-18.43M | $-19.12M | $-25.26M | $-23.89M | $8.19M | $-129.28M |
High Forecast | $67.17M | $58.51M | $68.70M | $-17.07M | $-13.65M | $-16.12M | $-15.25M | $5.23M | $-103.43M |
Low Forecast | $127.62M | $111.16M | $130.52M | $-20.48M | $-20.48M | $-30.63M | $-28.98M | $9.94M | $-155.14M |
Surprise % | - | - | - | - | - | - | 6.35% | -14.19% | 1.00% |
Forecast
Gracell Bio SG&A Forecast
Quarter
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
SG&A | - | - | - | - | - | - | $29.09M | $32.00M | $42.86M |
Avg Forecast | - | - | - | - | - | - | - | - | $42.86M |
High Forecast | - | - | - | - | - | - | - | - | $51.43M |
Low Forecast | - | - | - | - | - | - | - | - | $34.29M |
Surprise % | - | - | - | - | - | - | - | - | 1.00% |
Forecast
Gracell Bio EPS Forecast
Quarter
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
EPS | - | - | - | - | - | - | $-2.24 | $-1.77 | $-1.90 |
Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.27 | $-0.28 | $-0.37 | $-0.35 | $0.12 | $-0.05 |
High Forecast | $0.98 | $0.86 | $1.01 | $-0.25 | $-0.20 | $-0.24 | $-0.22 | $0.08 | $-0.03 |
Low Forecast | $1.87 | $1.63 | $1.91 | $-0.30 | $-0.30 | $-0.45 | $-0.42 | $0.15 | $-0.06 |
Surprise % | - | - | - | - | - | - | 6.40% | -14.75% | 38.00% |
Forecast
Gracell Bio Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
SPRO | Spero Therapeutics | $1.20 | $10.00 | 733.33% | Buy |
CHRS | Coherus BioSciences | $1.10 | $9.00 | 718.18% | Hold |
CTMX | CytomX Therapeutics | $0.87 | $5.73 | 558.62% | Buy |
INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
ABOS | Acumen Pharmaceuticals | $2.37 | $7.00 | 195.36% | Buy |
DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
ERAS | Erasca | $2.64 | $6.50 | 146.21% | Buy |
ASMB | Assembly Biosciences | $15.02 | $35.50 | 136.35% | Buy |
NXTC | NextCure | $1.30 | $3.00 | 130.77% | Buy |
DSGN | Design Therapeutics | $5.48 | $9.67 | 76.46% | Buy |
BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
AMLX | Amylyx Pharmaceuticals | $5.23 | $6.67 | 27.53% | Buy |
BPMC | Blueprint Medicines | $94.81 | $109.71 | 15.72% | Buy |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |